On April 18, 2026, President Donald Trump signed a sweeping executive order in the Oval Office that could reshape the future of mental health treatment in the United States. The order, which directs federal agencies to speed up research and regulatory review of psychedelic drugs—most notably the controversial compound ibogaine—marks a dramatic departure from decades of strict prohibition and limited scientific access.
Flanked by Health and Human Services Secretary Robert F. Kennedy Jr., podcaster Joe Rogan, and former Navy SEAL Marcus Luttrell, Trump declared, “Today’s order will ensure that people suffering from debilitating symptoms might finally have a chance to reclaim their lives and lead a happier life. They’ve been through so much.” According to CBS News, the president emphasized the potential for these drugs to change countless lives, especially for veterans battling post-traumatic stress disorder (PTSD) and traumatic brain injuries (TBI).
Ibogaine, a naturally occurring psychoactive compound derived from a West African shrub, has long been touted by advocates and some researchers as a promising therapy for hard-to-treat conditions such as opioid addiction, severe depression, and PTSD. But despite mounting anecdotal evidence, its Schedule I classification—placing it alongside heroin and ecstasy—has made rigorous scientific study in the U.S. nearly impossible. Americans seeking ibogaine treatment have often traveled to clinics in Mexico or the Caribbean, where the drug is administered outside U.S. regulatory oversight.
The new executive order aims to change that. As reported by The Associated Press, the order will remove many of the legal and bureaucratic barriers that have stymied research for decades. It establishes new FDA protocols for the "safe therapeutic use" of psychedelics, improves data sharing on studies, and calls for the first-ever human trials of ibogaine in the United States. FDA Commissioner Marty Makary announced that three psychedelics would be added to the National Priority Voucher pilot program, a move intended to reduce drug review times from months to weeks for compounds that align with national health priorities.
“If these turn out to be as good as people are saying, it’s going to have a tremendous impact,” Trump said during the signing, according to AP. “You’re going to save a lot of lives through it,” Luttrell told the president, echoing the hope shared by many in the room. Rogan, who has championed ibogaine on his widely followed podcast, recounted how he texted Trump information on the drug and received a swift reply: “Sounds great. Do you want FDA approval? Let’s do it.”
The executive order is more than just symbolic. It directs the Department of Health and Human Services to invest at least $50 million into states that have enacted or are developing programs to advance psychedelic research for serious mental illness. This federal-state partnership will provide funding, technical assistance, and data sharing—a model that mirrors the $50 million investment Texas made in ibogaine research last year, following advocacy from veterans groups and former Texas Governor Rick Perry.
Americans for Ibogaine CEO W. Bryan Hubbard, present at the signing, was visibly moved, embracing Rogan after the order was finalized. “The stigma around Schedule I drugs is significant,” Ismail Lourido Ali of the Multidisciplinary Association for Psychedelic Studies told AP. “It feels like this would give pretty substantial cover for Republican governors and legislatures to step into the ring in terms of funding research programs at their universities.”
The urgency behind the order is clear. More than 14 million American adults are diagnosed with serious mental illness, and over 6,000 U.S. veterans die by suicide each year, according to the White House. Traditional treatments have failed many, and the promise of new therapies has generated rare bipartisan support. Centers for Medicare & Medicaid Services Administrator Dr. Mehmet Oz called the order “an entire paradigm shift away from a one-day-a-pill model, which has failed so many and to many who are drug resistant … It offers them a way of getting out of that rut. The question now is, can we study why it works, to understand it better, to use it better?”
Preliminary research, while promising, remains limited. One small Stanford University study cited by AP involved 30 veterans treated with ibogaine in Mexico. Participants reported improvements in symptoms of traumatic brain injury, including PTSD, depression, and anxiety. However, the study lacked a placebo group, a crucial element for scientific rigor, and broader clinical trials are needed before the drug can be considered safe or effective for widespread use. As CBS News notes, only one double-blind, placebo-controlled randomized clinical trial has been completed so far, and a recent review of 24 studies involving 705 people called the risk of death from heart problems “worrying.” At least 27 deaths have been linked to ibogaine, largely due to its potential to cause dangerous heart rhythm disturbances.
Clinics that administer ibogaine, such as Beond Ibogaine in Cancun, typically charge between $15,000 and $20,000 per person. Last year, Beond treated roughly 2,000 people, including about 100 veterans who received free care. “There will be no insurance coverage, it will still be considered unapproved and non-covered care,” said Tom Feegel of Beond Ibogaine. “But what it does mean is that ibogaine shifts from being fringe and underground to being federally acknowledged.”
The FDA’s move to issue national priority vouchers for three psychedelics is unprecedented. According to AP, this mechanism will allow certain drugs to be approved quickly if they align with national priorities. Government-sanctioned treatments could begin as soon as this summer, pending FDA authorization, officials said. The order also opens a pathway for ibogaine to be administered to “desperately ill patients” under the FDA’s Right To Try rule, providing hope to those who have exhausted other options.
Despite the optimism, experts caution that more research is essential. Frederick Barrett, director of the Johns Hopkins Center for Psychedelic and Consciousness Research, told AP, “If the executive order can pave the way for doing objective, scientific research with this compound, it would help us understand whether it is truly a better psychedelic therapy than others.”
During the signing ceremony, Trump even joked about asking for ibogaine himself, a moment captured in a short video clip circulated by major outlets. The lighthearted exchange underscored both the novelty and the gravity of the occasion. As Joe Rogan later remarked, “They told me how impactful this medicine is. Having that conversation with them, millions of people got a chance to hear their story, hear the stories of all the different people that have had life-changing experiences from it.”
With the stroke of a pen, the U.S. government has set in motion a new era of psychedelic research—one that could offer hope to millions, but will require careful navigation of both scientific promise and real medical risks.